|
Pemigatinib Clinical Trials
11 actively recruiting trials across 4 locations
▲ +1 trial since August 2026
Also known as: INCB 054828, INCB-054828, INCB054828, PEMAZYRE, Pemazyre +1 more
Pipeline
Phase 1: 2Phase 2: 9
Top Sponsors
- UNICANCER1
- Tianjin Medical University Cancer Institute and Hospital1
- The Netherlands Cancer Institute1
- Sameek Roychowdhury1
- Ohio State University Comprehensive Cancer Center1
Indications
- Cancer11
- Unresectable Gallbladder Carcinoma1
- Unresectable Extrahepatic Cholangiocarcinoma1
- Unresectable Ampulla of Vater Carcinoma1
- Stage IV Gallbladder Cancer AJCC v81
Other5 trials
Birmingham, Alabama2 trials
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ohio State University-Telemedicine
Phase 2
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
University of Alabama at Birmingham
Phase 2
Boston, Massachusetts2 trials
PH 2 Pemigatinib in SDH-deficient GIST
Dana Farber Cancer Institute
Phase 2
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
Phase 1
Columbus, Ohio1 trial
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Ohio State University Comprehensive Cancer Center
Phase 2
Portland, Oregon1 trial
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.